OncoPatch is a Colorado company developing a patch that treats non-melanoma skin cancer with low-energy beta radiation, applied to the lesion in a doctor's office. Clinical studies are ongoing.
OncoPatch, Inc. develops a non-invasive treatment for non-melanoma skin cancers, basal cell carcinoma and squamous cell carcinoma, using low-energy beta therapy: an applicator held on the lesion with a silicone bandage in the doctor's office. Its website gives an address in Aurora, Colorado (NIH RePORTER lists Centennial) and states that clinical studies are ongoing. In fiscal year 2026 NCI awarded it USD 305,893 under STTR Phase I grant 1R41CA310335-01, Activated GaP-32 for the Treatment of Non-Melanoma Skin Cancer, with researchers at the Colorado School of Mines and the University of Colorado Anschutz.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI STTR Phase I (R41) award 1R41CA310335-01: Activated GaP-32 for the Treatment of Non-Melanoma Skin Cancer | 2026 | $306K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
The OncoPatch applicator is a patch from OncoPatch that treats basal cell and squamous cell skin cancers with short-range beta radiation in the doctor's office. It is in clinical studies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/